ID: ALA3321923

Max Phase: Preclinical

Molecular Formula: C30H31N5O6

Molecular Weight: 557.61

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(CC(=O)NC(=N)N[C@H](Cc2ccccc2)C(=O)NCCN2C(=O)c3ccccc3C2=O)cc1OC

Standard InChI:  InChI=1S/C30H31N5O6/c1-40-24-13-12-20(17-25(24)41-2)18-26(36)34-30(31)33-23(16-19-8-4-3-5-9-19)27(37)32-14-15-35-28(38)21-10-6-7-11-22(21)29(35)39/h3-13,17,23H,14-16,18H2,1-2H3,(H,32,37)(H3,31,33,34,36)/t23-/m1/s1

Standard InChI Key:  ZVHZJFRBDYJHEP-HSZRJFAPSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 557.61

Molecular Weight (Monoisotopic): 557.2274

AlogP: 1.91

#Rotatable Bonds: 11

Polar Surface Area: 149.92

Molecular Species: NEUTRAL

HBA: 7

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 11.37

CX Basic pKa: 8.08

CX LogP: 2.36

CX LogD: 1.60

Aromatic Rings: 3

Heavy Atoms: 41

QED Weighted: 0.16

Np Likeness Score: -0.60

References

1. Grädler U, Czodrowski P, Tsaklakidis C, Klein M, Werkmann D, Lindemann S, Maskos K, Leuthner B..  (2014)  Structure-based optimization of non-peptidic Cathepsin D inhibitors.,  24  (17): [PMID:25086681] [10.1016/j.bmcl.2014.07.054]

Source

Source(1):

• Scientific Literature